- Home
- YARW vs CUE Comparison
YARW vs CUE Comparison
Compare YARW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YARW | CUE |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.5M | 177.0M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | YARW | CUE |
|---|---|---|
| Price | $15.43 | $18.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $57.00 | ★ $88.00 |
| AVG Volume (30 Days) | ★ 157.3K | 144.7K |
| Earning Date | 11-17-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $14.08 | $0.17 |
| 52 Week High | $44.28 | $45.50 |
Technical Indicators
Market Signals| Indicator | YARW | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 41.93 |
| Support Level | N/A | $18.20 |
| Resistance Level | $20.49 | $22.49 |
| Average True Range (ATR) | 1.95 | 1.87 |
| MACD | -0.19 | 0.29 |
| Stochastic Oscillator | 36.02 | 39.06 |
Price Performance
Historical ComparisonAbout YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.